The trial previously met its primary endpoint in July 2017, showing a statistically-significant and clinically-meaningful improvement in progression-free survival.
News
Five-year framework for community pharmacy funding announced
The framework agreement for community pharmacies announced funding of almost £13 billion over five years.
Skills shortages ‘severely impacting’ NHS
The Edge Foundation reported that there are 41,000 nurse vacancies alone, but also problems in medicine, adult social care and particularly in mental health.
Keytruda, chemo combo recommended by NICE for lung cancer
The recommendation was supported by data from the Phase III KEYNOTE-407 trial.
Pharma & patient organisation collaborations could ‘improve patient care’
The survey revealed that patients, regardless of their country or disease state, highly value services from patient organisations and prefer them over those from pharmaceutical companies.
£250M boost for artificial intelligence & NHS
The investment will “help the NHS to become a world leader in artificial intelligence and health research.”
Cancer Research UK, Hummingbird join forces on anti-HER3 antibody drug
If successful, HMBD-001 could be used in the treatment of multiple cancers and be effective against drug resistant cancers.
New early breast cancer option recommended by NICE
The drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had.
First patient dosed in Astellas’ late-stage menopause trial
The study will evaluate the drug in menopause related vasomotor symptoms, such as hot flashes and night sweats.
NHS approves app for cancer related fatigue
Fatigue is one of the most common side effects of cancer and its treatment, with 70-80% of patients affected.
Trial success for Lynparza in prostate cancer
The treatment is the only PARP inhibitor with positive Phase III results in four different cancer types – ovarian, breast, pancreatic and prostate.
Verona Pharma share positive ensifentrine results in COPD
The trial consisted of 37 patients with moderate-to-severe COPD, who received a single dose of either the drug or a placebo.
Tecentriq, chemo combo shows bladder cancer promise
Tecentriq was the first cancer immunotherapy approved in bladder cancer.
Rivipansel flunks Phase III sickle cell trial
The trial was for patients six and older with the disease who required treatment with IV opioids for occlusive crisis.
New blood test ‘highly accurate’ at early Alzheimer’s identification
The test can measure levels of the Alzheimer’s protein amyloid beta in the blood.
